Investigation of relationships among upper abdominal symptoms, findings of esophagogastroduodenoscopy (EGD) and quality of life (QOL) and comparing study of therapeutic effects of various gastrointestinal drugs on upper abdominal symptoms of patients with functional dyspepsia (FD) or non-errosive reflux disease (NERD) by using questionnaires to evaluate upper abdominal symptoms (GOS) and QOL (SF-8).

Trial Profile

Investigation of relationships among upper abdominal symptoms, findings of esophagogastroduodenoscopy (EGD) and quality of life (QOL) and comparing study of therapeutic effects of various gastrointestinal drugs on upper abdominal symptoms of patients with functional dyspepsia (FD) or non-errosive reflux disease (NERD) by using questionnaires to evaluate upper abdominal symptoms (GOS) and QOL (SF-8).

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2016

At a glance

  • Drugs Famotidine (Primary) ; Mosapride (Primary) ; Rabeprazole (Primary) ; Teprenone (Primary)
  • Indications Gastro-oesophageal reflux; Non-ulcer dyspepsia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2012 Actual end date (Dec 2010) added as reported by University Hospital Medical Information Network - Japan record.
    • 03 Apr 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 15 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top